Idiopathic Parkinsonism treated with an extracerebral decarboxylase inhibitor in combination with levodopa.
The clinical actions of levodopa in Parkinsonism, given with and without an extracerebral decarboxylase in hibitor, L-alpha-methyldopahydrazine, were compared. Twenty-one patients were investigated in a "double-blind cross-over" study, administering levodopa in maximum tolerated dosage. L-Alpha-methyldopahydrazine failed to augment the overall therapeutic actions of levodopa but it consistently alleviated nausea. It is concluded that L-alpha-methyldopahydrazine will prove useful in the management of some Parkinsonian patients who have difficulty in taking levodopa alone.
D000328:Adult; D000368:Aged; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D002986:Clinical Trials as Topic; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage* / Q000009:adverse effects; D004357:Drug Synergism; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D008297:Male; D008750:Methyldopa / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy; D010300:Parkinson Disease / Q000188:drug therapy*; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy
D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D006834:Hydrazines; D008750:Methyldopa; D004295:Dihydroxyphenylalanine